Xeris Pharmaceuticals Inc. (XERS) Provides Business Update During Recent Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
November 21, 2019 6:00 AM ESTMAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE PFS launch underwayGVOKE HypoPen expected to launch July 2020CHI program shifts to Expanded AccessHAAF program discontinued based on Phase 2 results
CHICAGO, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,... More
